Clinical Trial Update: Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of CLAG plus selinexor in relapsed or refractory acute myeloid leukemia completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CLAG
• Selinexor (selinexor)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-03-13